Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 255 Breast Neoplasms 218 Lung Neoplasms 206 Glioblastoma 202 Head and Neck Neoplasms 193 Prostatic Neoplasms 179 Squamous Cell Carcinoma of Head and Neck 171 Lymphoma 152 Rectal Neoplasms 138 Esophageal Neoplasms 125 Central Nervous System Neoplasms 122 Leukemia 111 Brain Neoplasms 106 Pancreatic Neoplasms 96 Precursor Cell Lymphoblastic Leukemia-Lymphoma 93 Gliosarcoma 87 Esophageal Squamous Cell Carcinoma 84 Sarcoma 82 Uterine Cervical Neoplasms 81 Lymphoma, Follicular 81 Neoplasms 80 Lymphoma, Large B-Cell, Diffuse 80 Lymphoma, Non-Hodgkin 75 Hodgkin Disease 74 Glioma 68 Burkitt Lymphoma 67 Colorectal Neoplasms 66 Leukemia, Lymphocytic, Chronic, B-Cell 63 Astrocytoma 63 Neoplasm Metastasis 60

Interventions

Sorafenib 2 nimotuzumab 1 lenvatinib 1 atezolizumab 1 Tirapazamine 1 Stents 1 Radiotherapy 1 Radiosurgery 1 Radiofrequency Ablation 1 Immune Checkpoint Inhibitors 1 Hematologic Tests 1 Ethiodized Oil 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

HCC × Radiotherapy × Clear all

NCT06823375 2026-03-04

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

Chinese University of Hong Kong

Phase 2 Recruiting

HCC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡